Calcium carbonate/magnesium carbonate combination chewable tablets may be an alternative phosphate binder to calcium carbonate tablets with suspected potential advantages of synergistic phosphate binding. The major limitation of calcium carbonate phosphate binding capacity in hemodialysis patients (HD) is the co-administration of acid-suppressing drugs like proton pump inhibitors which slow the dissolution rate of calcium carbonate tablet and decrease its phosphate binding capacity.
INTRODUCTION:
Healthy kidneys are very necessary for cells functioning by maintaining the extracellular environment. This is achieved by specifically adjusting theurinary excretion of water and electrolytes to match net intake and excretion of wasteproducts of metabolism, such as creatinine, urea, and uric acid 1 .
When the amount offunctioning kidney tissue is greatly diminished, chronic kidney disease (CKD) will develop.End-stage renal disease (ESRD) is reached when the renal function drops below 10 to 15percent of the normal function 2 . Unless renal replacement therapy is started when ESRD occurs, it rapidly leads to death 3 . The most common type is hemodialysis (HD), in which waste products are removed from the body by diffusion mechanism across a non-biological semipermeable membrane in an artificial kidney. HD is usually performed at a dialysis center from two to three times per week for three to four hours 4 .
Phosphorus serum levels are usually within normal range until the GFR falls below approximately 30 ml/min according to the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF:K/DOQI) classification 5 and with continuing phosphate ingestion, reducing bone uptake of phosphate or increasing release of phosphate from high turnover bone hyperphosphataemia will occur.
Administration of dietary phosphorus binders in attempt to block intestinal.In addition, stage 5 chronic kidney disease patients were recommended to undergo hemodialysis to facilitate phosphates removal from blood that was already absorbed. However, four decades after the introduction of chronic hemodialysis in early 1960s, we have not yet found the ideal phosphate binder(s) in terms of combined efficacy, safety, availability, disintegration time, low pill burden, activity over a wide pH range, and low cost. There are multiple pharmacological options available for use as phosphate binders. Many studies assessing the efficacy and safety of these agents are available 6 . Magnesium carbonate (MgCO 3 ) and magnesium hydroxide [Mg (OH) 2 ] have been administered either alone or in combination with calcium salts with good results 7 . As renal function further deteriorates to CKD Stages 4 and 5, the quantitative excretion of magnesium tends to decrease and cannot be compensated any longer by an increased fractional excretion of magnesium 8 . This first becomes apparent as creatinine clearance falls <30 mL/min and particularly <10-15 mL/min. Thus, overt hypermagnesaemia develops frequently in patients with creatinine clearances <10 mL/min. As such, renal failure patients might be more vulnerable to changes in magnesium intake via the diet or via medication (e.g. antacids or phosphate binders) 9 , so that these compounds are not widely used in ESRD patients because nephrologists have an inordinate fear of hypermagnesemia and the belief that Mg administration frequently is accompanied by pH affects both the rate of dissolution of the salt and the subsequent binding reaction between the metal ion and phosphate. Generally, a very acidic pH is best to dissolve and ionize the salt 10 . Then, the metal ion must combine with inorganic phosphorus and this reaction may also be pH dependent. The optimal pH for these two reaction steps may be very different. For example, CaCO 3 is most soluble at pH 1 to 3, but calcium to phosphate binding is optimal above pH 5 11 . Ionized calcium binding to phosphorus is very pH dependent and decreases sharply below pH 5, so that CaCO 3 , the most widely used calcium salt, dissolves best in a very acid milieu and thus hypo or achlorhydria caused by using either H 2 -Blockers 12 or proton pump inhibitors (PPIs) 
The Impact of Study:
Since, the patients with ESKD are frequently associated with gastro-duodenal ulcers and erosive gastritis, and the use of either H 2 -Blockers or PPIs are the base for the treatment of these complications, and since the using of these acid secretion inhibitors will compromise CaCO 3 tablet dissolution and reduce its efficacy as a phosphorus binder, it is important to minimize this interaction by increasing the dissolution rate of phosphate binder by increasing the surface area of contact between gastric content and phosphate binder particles. This can be done by chewing or sucking a palatable tablet.
The
CaCO 3 /MgCO 3 combination chewable tablet (Rennie ® ) is a chewable tablet with peppermint flavor, which contains 80 mg MgCO 3 and 680 mg CaCO 3 , so that chewing or sucking two tablets of CaCO 3 /MgCO 3 combination chewable tablet after a meal will be almost equal in mg basis of calcium content to swallowing one tablet of CaCO 3 1250 mg with a meal. In addition, the 80 mg of MgCO 3 in CaCO 3 /MgCO 3 combination chewable tablet may add an additional phosphate binding activity to the 680 mg of CaCO 3 due to magnesium phosphate binding effect.
This study is important to identify ifCaCO 3 /MgCO 3 combination chewable tablets (Rennie ® ) have a superior efficacy and/or safety as phosphate binder without increasd risk of hypermagnesemia in comparison to CaCO 3 tablets in HD patients who are taking PPIs.
METHODS

Study design:
Randomized, controlled, open label study was conducted at renal /hemodialysis unit of KHMC and JUH, Amman, Jordan.HD patients were randomly allocated into interventional groups (Group I) or control groups (Group II) after they accepted to participate in this study.
All possible retrospective data for Group I and Group II were collected before the study period was started. The retrospective data that we collected (data of three months ago for HD participants in renal /hemodialysis of JUH and KHMC), included the last three values of serum PO4 -3 levels, serum Mg +2 levels,and the number of CaCO 3 tablets per day (N 1 )in addition to the baseline values of these parameters After retrospective data were completed, the two studied groups were followed for 6 weeks in which the following outcomes were measured or assessed in the following basis:  Serum PO4 -3 level was measured on weekly basis for the first 2 weeks and then every other week . +2 level was ≥4.5 mg/dl ,we dropped-out the HD participant from our study.The CaCO 3 tablets in Group II was kept without any change in the prospective follow-up phase.
Ethical approval:
The study was approved by the Scientific Committee of the Faculty of Pharmacy/The University of Jordan and the Faculty/Postgraduate Studies at the University of Jordan, In addition to ethical approval from the IRB committees at the Jordanian Royal Medical Services and JUH.
Study setting:
The patients in the renal /hemodialysis unit of KHMC and JUH who did met the inclusion and didn't met the exclusion criteria were enrolled in this study and after they signed an informed consent form, all were randomly allocated into either interventional group (Group  I) or control group (Group II) (www.randomization.com). Then, the data collection took place after the patients accepted to participate into the study.
Sample size:
The sample size of this study was a convenient sample. The total sample size was 36 HD participants, 13 HD participants were from renal /hemodialysis unit of JUH and 23 HD participants were from renal /hemodialysis unit of KHMC.
Study subjects:
The study subjects included all HD participants in the renal /hemodialysis unit of KHMC and JUH who did met the inclusion criteria and didn't met the exclusion criteria and who accepted to participate in this study after consent form signing and random allocation into the four different study groups.
Inclusion Criteria:
The inclusion criteria for HD participants in this study included: Age greater than 18 years, age lower than 60 years, on chronic hemodialysis for at least three months, the HD participants used CaCO 3 tablets as a phosphate binder and used PPIs as an acidsuppressive agents for at least 3 months before participating in this study.
Exclusion Criteria:
The exclusion criteria for HD patients in this study included: Serum cCa +2 level above 10.2 mg/dl , cCa +2 ×PO4 -3 above 55 mg²/dl², serum Mg +2 baseline level above 3.5 mg/dl, there was a positive history of psychiatric or other disorders leading to compliance issues, and there was a positive history of dysphagia or swallowing disorders or bowel obstruction.
Procedures:
Blood samples were drawn from the HD participants before HD session and heparin infusion were started. The tests of serum PO4 -3 and serum Mg +2 were performed within 1-2 hours after the unheparizined blood was immediately separated by centrifugation in the KHMC and JUH chemistry laboratories. The N 1 and N 2 were obtained directly from HD participants.
Data analysis
After follow-up part of this open label randomized controlled trial was finished at the end of 6 weeks. The collected data of each outcome in the different two studied groups were analyzed using SPSS software release 20.0.
Un-Paired t test analysis was used to present the demographic characteristics of age (years), body surface area (BSA) (m 2 ), body mass index (BMI) (kg/ m), duration of dialysis (months), duration of using CaCO 3 tablets as phosphate binder (months), duration of using PPIs (months) and HD duration per session (hours) by comparing the mean±SD among groups. In case of gender (male or female) and HD frequency per week (%) data were presented as percentage of frequency.
Unpaired t test was also used to analyze the serum PO4 -3 level and serum Mg +2 level by comparing the mean difference ±SD among two groups.
RESULTS:
Sample characteristics: Recruitment process:
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Assessed for eligibility N=284 Group I
Start of study (N=17)
One HD participant was dropedout from the study at week 2 due to persistent hypermagnesemia (3.5 mg/dl for 1 week.
One HD participant was dropedout from the study at week 2 due to WHO grading scale of diarrhea equal 3.
End of study (N=15)
Group II
Start of study (N=19)
There was no dropout during the 6 weeks of the study
End of study (N=19)
Excluded N=206
Not meeting inclusion criteria N=192
Other reasons N=6
Refused to participate N=8
Recruited N=36
Randomization
The recruitment, randomization, and dropout processes are summarized in Figure ( 1).
Figure 1: Recruitment, randomization, and dropout processes scheme.
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Demographics:
All demographic characteristics of 34 HD participants in the four studied groups are summarized in Tables (1-2) . The HD patient's medical history in each group of the four studied groups are summarized in Figure  ( 2). 
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The HD patient's medical history in each group of the four studied groups are summarized in Figure   story of the HD participant patients presented as (percentage).
The HD patient's medications in each group of the four studied groups are summarized in Figure ( 3).
history of the HD participant patients presented as (percentage).
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Between and within groups comparisons of serum PO4 -3 levels. Results of serum PO4 -3 levels analysis between the two studied groups are summarized in Tables (3) . Data are presented as Mean±SD and are analyzed by using Paired T-Test. Also, the between groups data are analyzed by using Unpaired T-Test.
-S*: Significant -N: Number of HD participants -NS: Non significant -PO4 -3 : phosphate
Between and within groups comparisons of Mg +2 levels. Results of serum Mg +2 levels analysis between and within two studied groups are summarized in Tables (4-5). 
DISCUSSION:
The effects of CaCO 3 /MgCO 3 combination chewable tablets versus CaCO 3 tablets on study parameters:
This study revealed that when CaCO 3 tablets were replaced by CaCO 3 /MgCO 3 combination chewable tablets. The serum PO4‾³ level was decreased significantly while the serum Mg+² level was increased significantly.
These results were explained depending on the pH effects on dissolution and binding kinetic of CaCO 3 tablet which can be summarized by "
The acidity is best for solubility, but binding to phosphorus is best at higher pH because at a low pH the higher H + concentration effectively competes with ionized calcium for binding to phosphorus"
1 . So, when the CaCO 3 tablets are taken with PPIs, the pH of stomach will be elevated and the acidity that is necessary to dissolve the CaCO 3 tablet will be decreased and then the phosphate binding capacity of CaCO 3 tablet will be decreased in contrast of CaCO 3 /MgCO 3 combination chewable tablet, there is no problem in dissolution after either chewing or sucking and so that, there is no drug interaction with PPIs on the dissolution step (rate-limiting step), in addition to that, the 
